Chun Jiang is an accomplished inventor based in Redwood City, CA (US). He has made significant contributions to the field of mitochondrial research, particularly in the development of compounds that target mitochondrial aldehyde dehydrogenase-2 (ALDH2). His work aims to provide new treatment options for patients suffering from Fanconi Anemia.

Latest Patents

Chun Jiang holds a patent for "Mitochondrial aldehyde dehydrogenase-2 binding compounds and methods of use thereof." This invention presents compounds that bind to ALDH2, along with methods for using these compounds to treat patients with Fanconi Anemia. The patent showcases his innovative approach to addressing critical health issues.

Career Highlights

Chun Jiang is currently associated with Aviv Therapeutics, Inc., where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on therapeutic strategies for genetic disorders.

Collaborations

Chun Jiang collaborates with notable colleagues, including Wenjin Yang and Yie-Teh Yu, who contribute to his research initiatives. Their combined expertise enhances the potential for groundbreaking discoveries in the field.

Conclusion

Chun Jiang's innovative work in mitochondrial research exemplifies the importance of targeted therapies in treating genetic disorders. His contributions are paving the way for new treatment options and improving patient outcomes.

Profile summary based on public USPTO records.